Announcement banner


NeuroBlu v3.1: Improved clinical features with ANSA & AIMS and refreshed data

May 10, 2023

Announcing NeuroBlu v3.1 with ANSA Integration for Enhanced Pharma and HEOR Research.

We are excited to introduce NeuroBlu v3.1, featuring the latest 23R2 database updates and the integration of the ANSA (Adult Needs and Strengths Assessment)  and the AIMS (The Abnormal Involuntary Movement Scale) scales. Here is what is new and improved:

What is New:

Integration of ANSA:

  • Evidence-based, comprehensive, and standardized assessment designed to evaluate the needs and strengths of adults in the behavioral health field.
  • Assesses a range of domains and modules, including psychological, emotional, social, and physical well-being, as well as support systems such as family and community resources.

         Provides valuable data for RWD research and potential use cases, including          tracking patient progress over time, identifying social determinants of health,          assessing treatment effectiveness, and developing targeted interventions.

Integration of AIMS:

         AIMS (The Abnormal Involuntary Movement Scale) is an assessment to .          measure the level of dyskinesias in patients taking neuroleptic medications.

         The scale was developed by the Psychopharmacology Research Branch of          the National Institute of Mental Health, and is widely used to assess tardive          dyskinesia in clinical trials of antipsychotic medications. In a clinical setting it          may be used for screening and monitoring of symptoms, for patients on          antipsychotic medications.

NeuroBlu Database 23R2 Updates:

  • Refreshed patient data from all data partners up to April 2023.
  • Improved existing clinical features, such as MSE, with bug fixes and enhancements.

What has Improved:

Code Studio:

  • Now supports importing Template projects, providing a smoother and more efficient experience for users.

General Improvements:

  • We have implemented various bug fixes and security improvements to ensure a seamless and secure experience for all our users.

We encourage you to leverage the latest NeuroBlu v3.1 and take advantage of the ANSA and AIMS integration to improve your data-driven decision-making and analysis in pharma and HEOR research!

Explore NeuroBlu

Printer button icon.Share button icon.
Back to top
Contact us